Giessen, Germany (PROTEXT/ots) - Diabetes mellitus and cancerare among the diseases of greatest clinical focus. At the ScheBoBiotech AG Symposium during MEDICA on the occasion of the WorldCongress of Pathology and Laboratory Medicine (WASPaLM) 2001 twospecific diagnostic tools with unique clinical approaches will bepresented.
Since the availability of the ScheBo Pancreatic Elastase 1stool test, which fulfils all the criteria of a screening test,exocrine pancreatic disturbances can be easily detected withoutstressing the patient, leading to an appropriate treatment.Moreover, strong evidence has shown that the endocrine pancreaticsystem (diabetes mellitus) is very closely linked to the exocrinesystem, and they are influenced by each other.
The decision of the right therapy is one of the majorclinical challenges in oncology. Looking for primary effects ofcarcinogenesis will give additional information about thedevelopment of cancer at an early stage ScheBo Tumor M2-PKdetects a metabolic switch in cancer cells reflecting theavailability of new compounds necessary for fast growth. Thismeaningful metabolic change is highly specific for tumour cellsand not observed in normal proliferating cells. Thus, checkingthe metabolic state of cancer cells will be the future tool ofclinicians to assess the therapy and follow-up the patient. A newconcept in diagnosing and following-up patients approaches theoncological clinic.
Topics are:
- Pancreatic Elastase 1 - A Screening Marker for the SecondMetabolic Syndrome in Patients with Diabetes Mellitus - A Unique Approach for Clinical Practice using the TumorMetabolic Marker Tumor M2-PK
Venue: MEDICA Congress Centre (CCD South), DuesseldorfGermany
Date: Thursday 22nd November 2001, 14:00 - 17:00 Pleaserefer to our website for further information: www.schebo.com.ots Original Text Service: ScheBo Biotech AG Internet:http://www.presseportal.de Contact: Dr. Martin SchoendorfProduct Group Manager International ScheBo Biotech AGNetanyastrasse 3 - 5 D-35394 Giessen/ Germany Tel.: +49-(0)641-4996-0 Fax: +49-(0)641-4996-77
Subscribers please note that material bearing the slug"PROTEXT" is not part of CTK's news service and is not to bepublished under the "CTK" slug. Protext is a commercial serviceproviding distribution of press releases from clients, who areidentified in the text of Protext reports and who bear fullresponsibility for their contents.
PROTEXT
